Neuropathic cancer pain: What we are dealing with? How to manage it?

Esin, Ece; Yalçın, Şuayib

doi:10.2147/ott.s60995

Cited by 35 publications

(41 citation statements)

References 204 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Approximately 60% of cancer patients suffer from neuropathic pain (Pachman, Barton, Swetz, & Loprinzi, 2012). Esin & Yalcin, 2014;Fallon, 2013;Pachman et al, 2012;Yoon & Oh, 2018).…”

Section: Canadian Pain Society (Cps) European Federation Ofmentioning

confidence: 99%

Duloxetine and pregabalin in neuropathic pain of lung cancer patients

2020

View full text Add to dashboard Cite

Introduction Neuropathic pain occurs in 1% of the population and is difficult to manage. This chronic pain causes psychological distress and impacts patient's quality of life, especially in cancer patients. The aim of this study was to show and compare the efficacy of pregabalin and duloxetine, which are reported in the group of first‐line treatment at European Federation of Neurological Societies (EFNS) guidelines on the pharmacological treatment of neuropathic pain (2010 revision) in lung cancer patients by using visual analogue scale (VAS) and Leeds Assessment of Neuropathic Symptoms and Sign (LANSS). Patients and Methods A prospective, randomized, open label, 3 month of study was conducted. A total of 44 patients that were diagnosed with neuropathic pain (14 women and 30 men) were included in the study. Patient's LANSS and VAS values were recorded before treatment. Then, 22 patients undergo pregabalin and 22 patients undergo duloxetine therapy. But due to side effects (dizziness, constipation), two patients had stopped to use pregabalin. Their LANSS and VAS values were recorded after 1 and 3 months of therapy. Results When we compare LANSS and VAS scores before treatment, after 1 and 3 months of treatment with pregabalin and duloxetine, a significant decrease was observed in both groups at the 1 and 3 months (p < .01). Duloxetine is superior to pregabalin in reducing the LANSS scores when we compare two groups. Conclusions Both duloxetine and pregabalin are effective in the treatment of neuropathic pain of lung cancer patients. And as far as we know, this is the first study comparing the efficacy of duloxetine and pregabalin in the neuropathic pain of lung cancer patients.

show abstract

“…Approximately 60% of cancer patients suffer from neuropathic pain (Pachman, Barton, Swetz, & Loprinzi, 2012). Esin & Yalcin, 2014;Fallon, 2013;Pachman et al, 2012;Yoon & Oh, 2018).…”

Section: Canadian Pain Society (Cps) European Federation Ofmentioning

confidence: 99%

Duloxetine and pregabalin in neuropathic pain of lung cancer patients

2020

View full text Add to dashboard Cite

show abstract

“…Using a rat model of advanced OA pain, we tested the following hypotheses: 1) central sensitization is observed selectively in the context of ongoing joint pain associated with advanced OA pain and 2) duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI) prescribed for neuropathic pain 8, 23, 39 , blocks NSAID resistant ongoing joint pain.…”

Section: Introductionmentioning

confidence: 99%

Central Sensitization and Neuropathic Features of Ongoing Pain in a Rat Model of Advanced Osteoarthritis

Havelin

Imbert

Cormier

et al. 2016

The Journal of Pain

View full text Add to dashboard Cite

Osteoarthritis (OA) pain is most commonly characterized by movement-triggered joint pain. However, in advanced disease, OA pain becomes persistent, ongoing and resistant to treatment with NSAIDs. The mechanisms underlying ongoing pain in advanced OA are poorly understood. We recently showed that intra-articular (i.a.) injection of monosodium iodoacetate (MIA) into the rat knee joint produces concentration-dependent outcomes. Thus, a low dose of i.a. MIA produces NSAID-sensitive weight asymmetry without evidence of ongoing pain while a high i.a. MIA dose produces weight asymmetry and NSAID-resistant ongoing pain. In the present studies, palpation of the ipsilateral hindlimb of rats treated 14 days previously with high, but not low, doses of i.a. MIA produced FOS expression in the spinal dorsal horn. Inactivation of descending pain facilitatory pathways by microinjection of lidocaine within the rostral ventromedial medulla (RVM) induced conditioned place preference (CPP) selectively in rats treated with the high dose of MIA. CPP to intra-articular lidocaine was blocked by pretreatment with duloxetine (30 mg/kg, i.p. at −30 min). These observations are consistent with the likelihood of a neuropathic component of OA that elicits ongoing, NSAID resistant pain and central sensitization that is mediated, in part, by descending modulatory mechanisms. This model provides a basis for exploration of underlying mechanisms promoting neuropathic components of OA pain and for the identification of mechanisms that may guide drug discovery for treatment of advanced OA pain without the need for joint replacement.

show abstract

“…2 Although it is often a disabling feature of chronic conditions such as arthritis, 3 diabetes, 4 cancer, 5 cardiovascular disease, 6 HIV, 7 inflammatory bowel disease, 8 and autoimmune diseases, 9 chronic pain is now recognized as a disease in its own right. 10 Chronic pain affects more than six million Canadians of all ages and is most prevalent among women, Indigenous peoples, and older adults.…”

Section: Introductionmentioning

confidence: 99%

Researching what matters to improve chronic pain care in Canada: A priority-setting partnership process to support patient-oriented research

Poulin

Shergill

Romanow

et al. 2018

Canadian Journal of Pain

View full text Add to dashboard Cite

Background Chronic pain affects more than 6 million Canadians. Patients need to be involved in setting research priorities to ensure a focus on areas important to those who will be most impacted by the results. Aims The aim of this study was to leverage patient experiences to identify chronic pain research priorities in Canada. Method The process was informed by the James Lind Alliance. After gathering an exhaustive list of questions using surveys, town hall meetings, interviews, and social media consultations, we used a computerized Delphi with four successive iterations to select the final list of research priorities. The final Delphi round was conducted by a panel of ten patients living with chronic pain and ten clinicians from different disciplines. Results We received more than 5000 suggestions from 1500 people. The Delphi process led to the identification of 14 questions fitting under the following 4 themes: (1) improving knowledge and competencies in chronic pain; (2) improving patient-centered chronic pain care; (3) preventing chronic pain and reducing associated symptoms; and (4) improving access to and coordination of patient-centered chronic pain care. Challenges included the issue of chronic pain being ubiquitous to many diseases, leading to many initial suggestions focusing on these diseases. We also identified the need for further engagement efforts with marginalized groups in order to validate the priorities identified or identify different sets of priorities specific to these groups. Conclusion The priorities identified can guide patient-oriented chronic pain research to ultimately improve the care offered to people living with chronic pain.

show abstract

Neuropathic cancer pain: What we are dealing with? How to manage it?

Cited by 35 publications

References 204 publications

Duloxetine and pregabalin in neuropathic pain of lung cancer patients

Duloxetine and pregabalin in neuropathic pain of lung cancer patients

Central Sensitization and Neuropathic Features of Ongoing Pain in a Rat Model of Advanced Osteoarthritis

Researching what matters to improve chronic pain care in Canada: A priority-setting partnership process to support patient-oriented research

Contact Info

Product

Resources

About